Motley Fool  May 1  Comment 
A $4.3 billion acquisition provides additional growth opportunity for this European healthcare giant.
FiercePharma  Apr 25  Comment 
Fresenius pulls off sterile injectables double whammy, snags Akorn as well as Merck KGaA's biosimilars business epalmer Tue, 04/25/2017 - 09:38
MarketWatch  Apr 24  Comment 
Germany-based Fresenius Kabi will buy Akorn Inc. for $34 a share, plus the assumption of roughly $450 million of debt, for a deal valued at $4.3 billion, the companies said Monday. The deal is expected to close by early 2018 and will add to...
Yahoo  Apr 24  Comment 
Acquiring Akorn would add around $1 billion in annual sales to Fresenius' drugmaking division, giving it a significantly larger presence in eyecare and other areas widely perceived as somewhat insulated from generic drug pricing pressure. The deal...
Benzinga  Apr 21  Comment 
A number of stocks are looking strong technically this week with the market's upside reversal. Here are four to watch. Akorn, Inc. (NASDAQ: AKRX) had a strong reversal session on Tuesday, up $1.05 or 3.28%, to $33.04. After surging in the second...
Benzinga  Apr 19  Comment 
Akorn, Inc. (NASDAQ: AKRX) shares are drifting higher by 0.27 percent (about $0.10 per share) Wednesday after jumping 3.2 percent Tuesday following a report the company was on the verge of a buyout deal. Akorn shares jumped more than 3 percent...
Benzinga  Apr 11  Comment 
Last week, Fresenius Kabi, a subsidiary of Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS) said it was looking into the possibility of acquiring Akorn, Inc. (NASDAQ: AKRX). Since the announcement, shares of the latter have spiked more than 30...
Motley Fool  Apr 10  Comment 
Management confirmed that it was in buyout talks with Fresenius Kabi for the potential sale of Akorn.

You may also be interested in articles related to Akorn (AKRX):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki